Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Dexmedetomidine Sedation for AVF Creation in Uraemia
ChiCTR2500115430Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in end-stage kidney disease (ESKD) and uremia comparing Dexmedetomidine group with Remimazolam group (2 arms). Primary endpoint: Composite incidence of intraoperative sedation failure. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
remimazolamdexmedetomidine
03
Conditions
end-stage kidney disease (ESKD)uremia
Beyond the preview
Go deeper on ChiCTR2500115430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115430.